Debiopharm Group has signed a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl/Moapar three-month formulation. Salvacyl, a gonadotropin releasing hormone agonist analogue, is said to be effective in the treatment of severe sexual deviations in...
